J.P. Morgan 2024: Financial Forecast Is Sunny For Firms Poised For Pharma Deals

Clouds Seemed To Lift At Annual Industry Meeting

 
• By Mandy Jackson

Drug developers weathered a tough 2023, but the year ended with new clarity about interest rates and big pharma M&A priorities, reducing the risk of financial storms in 2024, investors and advisors said.

Sweeping view of a partly cloudy sunrise over the Ventura coastline
A new, sunnier day may be dawning in biopharma finance • Source: Shutterstock

More from Deal-Making

More from Scrip